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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYThe discovery of human-induced pluripotent stem cells (iPSCs) has sparked great interest in the potential treatment of patients with their
own in vitro differentiated cells. Recently, knockout of the Tumor Protein 53 (p53) gene was reported to facilitate reprogramming but
unfortunately also led to genomic instability. Here, we report that transient suppression of p53 during nonintegrative reprogramming
of human fibroblasts leads to a significant increase in expression of pluripotency markers and overall number of iPSC colonies, due to
downstream suppression of p21, without affecting apoptosis and DNA damage. Stable iPSC lines generated with or without p53 suppres-
sion showed comparable expression of pluripotencymarkers andmethylation patterns, displayed normal karyotypes, contained between
0 and 5 genomic copy number variations and produced functional neurons in vitro. In conclusion, transient p53 suppression increases
reprogramming efficiency without affecting genomic stability, rendering the method suitable for in vitro mechanistic studies with the
possibility for future clinical translation.INTRODUCTION
Dr.Wilmut and colleague’s discovery in 1996 thatmamma-
lian somatic cells can be reprogrammed into a totipotent
state of development by fusion with an enucleated oocyte
(Campbell et al., 1996) has paved the way for autologous
stem cell therapy by exploiting a patient’s own in vitro
differentiated cells. Ten years later, with the revolution-
izing finding that induced pluripotent stem cells (iPSCs)
can be established from somatic cells by overexpression
of merely four transcription factors (Takahashi and Yama-
naka, 2006), a major step toward a clinical translation
was taken. However, new coding mutations were recently
reported to arise during the reprogramming process (Gore
et al., 2011; Laurent et al., 2011; Martins-Taylor and Xu,
2012; Ng et al., 2011), rendering the process too hazardous
for regenerative use in humans.
Several nonintegrative reprogramming strategies includ-
ing Sendai virus (Fusaki et al., 2009) and episomal plasmids
(Okita et al., 2011, 2013; Yu et al., 2009) have been tested
to produce safe, transplantable iPSCs. Yet, recent whole-
genome sequencing studies have failed to demonstrate a
reduction in the mutational load in iPSC lines derived
by integration-free reprogramming methods (Gore et al.,
2011).
The cell-cycle regulator p53 acts as an important safe-
guard mechanism, by preventing cells from undergoing
uncontrolled proliferation in response to DNA damage404 Stem Cell Reports j Vol. 3 j 404–413 j September 9, 2014 j ª2014 The A(Hong et al., 2009). The downstream DNA damage
response (DDR) involves a series of events that lead to
either cell-cycle arrest induced by p21 or apoptosis induced
by PUMA. Importantly, p53 has also been shown to act
as a critical barrier to the reprogramming process, and
knockout of the TP53 gene in mouse and human fibro-
blasts was shown to produce significantly more iPSC col-
onies (Hong et al., 2009; Kawamura et al., 2009; Mario´n
et al., 2009). Although the inhibition of p53 is clearly ad-
vantageous for the reprogramming efficiency, knocking
out TP53 may possess critical safety issues because it was
found to cause genomic instability (Chen et al., 2012;
Lake et al., 2012; Mario´n et al., 2009; Menendez et al.,
2010).
Recently, transient suppression of p53 with nonintegra-
tive plasmids was shown to improve the reprogramming
efficiency of human fibroblasts (Okita et al., 2011) and
blood cells (Okita et al., 2013) by use of nonintegrative
plasmids. Yet it remains unknown whether transient sup-
pression of p53 will also give rise to genomic instability,
which may in turn have detrimental effects on the gene
expression, the epigenetic status, and the differentiation
capacity of the resulting iPSC lines.
In this study, we set out to establish an optimized nonin-
tegrative reprogramming approach under defined condi-
tions in order to study the functional effects of transient
p53 suppression in normal human dermal fibroblasts
(NHDFs) during and after reprogramming.uthors
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Increased Reprogramming Efficiency with Transient
p53 Suppression
To study the effect of transient p53 suppression during
reprogramming of human fibroblasts, a nonintegrative re-
programming system was established in defined condi-
tions (Figure 1A and Figure S1 available online). Seven
days after reprogramming with or without (w/wo) tran-
sient expression of a short hairpin to TP53 (shp53), a sub-
population of small, highly proliferative cells was observed
in both conditions (Figures 1B and 1F). At days 14–28, iPSC
colonies were observed (Figures 1C, 1D, 1G, and 1H),
which stained positive for TRA-1-81 (Figures 1E and 1I).
The growth rate was, in general, higher during reprogram-
ming with transient p53 suppression (0.12 cell doublings
per day) compared to without (0.06 cell doublings per
day), although not to a significant degree (Figure 1J). In
contrast, a fibroblast line, which stably express shp53
(PLK.O; Godar et al., 2008) displayed a significantly higher
growth rate (0.42 cell doublings per day), yet, this line
proved resistant to reprogramming (data not shown). Alka-
line phosphatase staining and counting on day 28 showed
a significant (7.5-fold) increase in the number of iPSC col-
onies with transient p53 suppression (0.12%) compared
to without (0.016%) (Figure 1K), which was confirmed in
several independent experiments comprising NHDFs
from different individuals.
Transient p53 Suppression Increases Reprogramming
Efficiency through Inhibition of p21 without
Affecting Apoptosis and DNA Damage
To investigate the underlying effect of the increased re-
programming efficiency with transient p53 suppression,
temporal changes in pluripotency markers (SSEA4, TRA1-
60), tumor suppression (p53), cell-cycle regulation (p21),
apoptosis (PUMA), and DNA damage (H2A.X) were stud-
ied by flow cytometry. Although the PLK.O line stably ex-
pressing shp53 showed a 43.6% reduction in p53-positive
cells compared to NHDFs, the pluripotency markers SSEA4
and TRA1-60 remained low during the entire reprogram-
ming experiment (data not shown). In contrast, the ana-
lyses revealed a significant increase in SSEA4 and TRA1-
60 double-positive cells with transient p53 suppression
on day 21 (10.0% versus 3.1%) and on day 28 (16.6%
versus 8.3%) after reprogramming (Figure 2A). A signifi-
cant decrease in p53-positive cells was also observed
with transient p53 suppression at days 7 (82.8% versus
90%), 14 (79% versus 92.7%), and 21 (63.8% versus
89.4%) (Figure 2B), which correlated with a significant
decrease in p21-positive cells at days 7 (92.6% versus
96.3%), 14 (87.9% versus 95.6%), and 21 (68.1% versus
93.4%) (Figure 2C). In contrast, no significant effect ofStem Celltransient p53 suppression on apoptosis was observed, as
evaluated by the proapoptotic marker PUMA (Figure 2D),
a mitochondrial membrane assay (Figure S2A), and An-
nexin V in TRA1-60-positive cells (Figure S2B). Moreover,
analysis with H2A.X, which is associated with replica-
tion-induced DNA damage (Garcia-Canton et al., 2012),
detected no significant effect of transient p53 suppression
on DNA damage, neither in the total cell population
(Figure 2E) nor in TRA1-60-positive cells (Figures S2C
and S2D).
Next, gene expression analysis of TP53 and its down-
stream DDR targets P21 and PUMA, as well as the plurip-
otency marker NANOG was performed. The silencing
effect of shp53 resulted in a significant decrease in TP53
expression in unsorted cells 7 days after reprogramming
(Figure S2E), and in P21 expression 14 days after re-
programming (Figure S2F), whereas expression of PUMA
was unaffected (Figure S2G). In addition, no significant
effect of shp53 suppression in TRA1-60-sorted cells was
observed (Figures S2I–S2K). In contrast, the pluripotency
marker NANOG was significantly upregulated in both un-
sorted and sorted cells 21 and 14 days after reprogram-
ming with shp53, respectively (Figures S2H and S2L).
iPSCs Generated by Transient p53 Suppression Display
Normal In Vitro Characteristics
To examine whether transient p53 suppression confers a
negative effect on the long-term stability, six iPSC lines
established w/wo transient p53 suppression were charac-
terized in detail. Overall, there were no differences in
morphology (Figures 3A and 3E). The pluripotency
markers OCT4, NANOG, SSEA3, SSEA4, TRA1-60, and
TRA1-81 were all detected by immunocytochemical stain-
ing (Figures 3B–3D and 3F–3H) and quantitative real-time
PCR analyses showed a comparable upregulation of
POU5F1 (OCT4), SOX2, NANOG, ZFP42, DNMT3B, and
TP53 and downregulation of P21 compared with NHDFs
(Figure 3I). Moreover, integration analyses confirmed
lack of expression from exogenous genes (Figure S3A). A
comparable hypomethylation of the pluripotency-associ-
ated genes OCT4, NANOG, SALL4, and RAB25 and hyper-
methylation of the fibroblast-associated gene UBE1L was
also observed (Figure 3J). Genome-wide transcriptome
profiling showed no significant up- or downregulated
genes in iPSC lines generated w/wo transient p53 suppres-
sion and analysis with PluriTest showed that all iPSC lines
scored within the predefined pluripotency and novelty
scores (Figure 3K). Finally, in vitro differentiation
confirmed by the ability to generate embryoid bodies (Fig-
ures 3L, 3M, 3P, and 3Q), which stained positive for Beta-
III-tubulin (TUJI) (Figures 3N and 3R), smooth muscle
actin (SMA), and alpha-fetoprotein (AFP) (Figures 3O
and 3S).Reports j Vol. 3 j 404–413 j September 9, 2014 j ª2014 The Authors 405
Figure 1. Increased Reprogramming with Transient p53 Suppression in Defined Conditions
(A) Timeline showing the reprogramming in defined conditions with the episomal plasmids hOCT4, hSOX2, hKLF4, hL-MYC, and hLIN28
(hOSKUL) with or without (w/wo) a short hairpin to p53 (shp53).
(B–D and F–H) Morphology of normal human dermal fibroblasts (NHDFs) and induced pluripotent stem cells (iPSCs) at days 7, 17, and 28
after reprogramming w/wo shp53.
(E and I) Tra-1-81 staining of primary iPSC colonies 28 days after reprogramming w/wo shp53.
(J) Growth rate of cells electroporated with hOSKUL, hOSKUL + shp53, or a fibroblast line stably expressing shp53 (PLK.O) at days 7, 21, and
28 after reprogramming.
(K) Alkaline phosphatase staining and counting of primary iPSC colonies at day 28 after reprogramming w/wo shp53.
Scale bars, 200 mm (B, C, F, and G) and 400 mm (D, E, H, and I). Y error bars depict SD of three independent experiments. *p < 0.05. See also
Figure S1.
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Figure 2. Transient p53 Suppression Increases Reprogramming Efficiency without Affecting Apoptosis and DNA Damage
Flow cytometry of normal human dermal fibroblasts (NHDFs) on days 0, 7, 14, 21, and 28 after reprogramming with the episomal plasmids
hOCT4, hSOX2, hKLF4, hL-MYC, and hLIN28 (hOSKUL) with or without (w/wo) a short hairpin to p53 (shp53).
(A–E) Flow cytometry was performed with (A) the pluripotency markers SSEA4 and TRA1-60, (B) the tumor suppressor p53, (C) the cell-
cycle regulator p21, (D) the proapoptotic marker PUMA, and (E) the double-stranded DNA damage marker H2A.X.
(F) Overview depicting the mechanisms involved in transient p53 suppression during reprogramming. Y error bars depict SD of three
independent experiments. *p < 0.05. See also Figure S2.
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Genomic Stability
The genomic stability of fibroblasts and iPSC lines gener-
ated w/wo transient p53 suppressionwas analyzed in detail
by chromosome studies and copy number variation (CNV)
analyses. All the lines presented normal karyotype and did
not contain any microscopically visible structural or nu-
merical abnormalities (46, XY) (Figure S3B). CNV analyses
showed no significant differences between the numbers
of CNVs in iPSC lines generated w/wo transient p53 sup-
pression, displaying an average of 1.66 genomic CNVs
(four gains and six losses), which were not present in the
donor NHDFs (Table S1). Three of the CNVs were detected
in iPSC lines without transient p53 suppression, with one
line containing two CNVs (K1), one line containing a
single CNV (K3), and one line containing no CNVs (K2).
In contrast, seven of the CNVs were detected in iPSC lines
with transient p53 suppression, with one line (K1_shp53)
containing five CNVs, whereas the other two lines
(K2_shp53 and K3_shp53) had only a single CNV each,
the latter in a noncoding region.
iPSCs Generated by Transient p53 Suppression Can
Differentiate to Functional Neurons In Vitro
To evaluate the differentiation potential of iPSC lines estab-
lished w/wo transient p53 suppression, directed neural dif-Stem Cellferentiation was performed (Figure 4A). At day 12, all the
iPSC lines had formed a uniform monolayer of tightly
packed neuroepithelial cells (Figures 4B and 4F), and at
days 21, a population of neural progenitor cells (NPCs)
was formed, which stained positive for the NPC markers
SOX2, NESTIN (Figures 4J and 4N), andVIMENTIN (Figures
4K and 4O), whereas OCT4 was negative. After subsequent
culture and passage for 35 days, a network of neural struc-
tures was observed (Figures 4D and 4H), containing neu-
rons with a bi- or multipolar morphology with long axonal
connections (Figures 4E and 4I). At this stage, most of the
cells stained positive for TUJI (Figures 4L and 4P) and the
glutamatergic marker vGLUT (Figures 4M and 4Q). Func-
tional characterization on day 80 showed that the iPSC
lines responded to glutamate/glycine (Figures 4R and 4T),
GABA, and acetylcholine (Figures 4S and 4U), indicating
the presence of receptors for these neurotransmitters.DISCUSSION
In this study, we report the establishment of a noninte-
grative reprogramming approach in defined conditions,
based on transient suppression of p53. Using this
method, we were able to consistently generate AP and
TRA1-81-positive iPSC colonies from individuals withReports j Vol. 3 j 404–413 j September 9, 2014 j ª2014 The Authors 407
(legend on next page)
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Effects of Transient p53 Suppression on Human iPSCsdifferent genders and ages. Compared to the results of
Okita et al. (2011), who reported an average of 30 iPSC
colonies per 1 3 105 human fibroblasts (0.03%), we ob-
served a 3-fold increase (0.11%) at defined conditions. In
contrast, a fibroblast line stably expressing shp53 did not
produce any iPSC colonies, and it is likely that the uncon-
trolled growth of this line has made it resistant to reprog-
ramming due to accumulation of DNA damage or severe
shortening of telomeres.
To study temporal changes during reprogramming with
transient p53 suppression, flow cytometry with the plurip-
otency markers SSEA4/TRA1-60, which were previously
used for isolation of fully reprogrammed iPSCs (Kahler
et al., 2013), was performed. A significant increase in
the amount of SSEA4/TRA1-60 double-positive cells was
observed on day 21 (3-fold) and on day 28 (2-fold) after
reprogramming with shp53. Moreover, transient p53 sup-
pression also accelerated the temporal appearance of fully
reprogrammed iPSCs, as the cells became earlier positive
for SSEA4/TRA1-60.
As expected from the silencing effect of shp53, p53 was
significantly suppressed during reprogramming with tran-
sient p53 suppression, which correlated with suppression
of p21, whereas expression of the proapoptotic marker
PUMA remained unchanged. These results imply that tran-
sient p53 suppression increases reprogramming by acti-
vating cell proliferation through p21 suppression, rather
than by decreasing apoptosis (Figure 2F). Moreover, the
effect of transient p53 suppression appears to occur in fi-
broblasts prior to reprogramming, because no significant
differences in TP53, P21, and PUMA were observed in
TRA1-60-sorted cells (Figures S2I–S2L). The latter is in
agreement with a recent study, which demonstrated that
embryonic stem cells (ESCs) possess a nonfunctional p53-
p21 axis, in which p53 activates specificmicroRNAs, which
inhibit p21 expression, thereby affecting cell-cycle regula-
tion (Dolezalova et al., 2012). In contrast, NANOG was up-Figure 3. iPSCs Generated by Transient p53 Suppression Display
(A–H) (A and E) Phase contrast morphology and (B–H) immunocytoch
with or without (w/wo) a short hairpin to p53 (shp53) with the pluri
TRA1-60, and Hoechst (C and G), and SSEA3, SSEA4, and Hoechst (D
(I) Quantitative real-time PCR with the pluripotency markers ZFP42, P
expression is shown as the fold change (2DDCt) with normal human d
was included.
(J) Schematic view of the methylation state of selected CpG sites in
separate clone and each circle represents a CpG site. Open circles re
sites.
(K) PluriTest algorithm results of transcriptome profiles including a ref
a density distribution for previously referenced pluripotent stem cell
(L–S) (L, M, P, and Q) Morphology of embryoid bodies (EBs) on day 7 (
staining of plated EBs on day 28 with TUJI (N and R), smooth muscle
Scale bars, 400 mm (A, E, L, M, P, and Q), 100 mm (B–D and F–H), or
Stem Cellregulated with transient p53 suppression in both unsorted
and TRA1-60-sorted cells; thus, NANOG could be a poten-
tial downstream target of p53. In addition, knockout of
tp53 in mouse fibroblasts was recently shown to increase
reprogramming through actions of p21 by promoting a
mesenchymal-to-epithelial (MET) transition (Brosh et al.,
2013), which could also apply in human.
Mario´n and colleagues previously reported that
knockout of TP53 in human and mouse fibroblasts allows
for efficient reprogramming at the expense of increased
DNA damage, which was attributed to a decrease in
apoptosis of DNA damaged cells (Mario´n et al., 2009). In
contrast, we found that transient p53 suppression did not
induce DNA damage or result in a decrease in apoptosis
during reprogramming. The underlying mechanism is
likely to constitute a combination of nonintegrative plas-
mids, which prevents excessive DNA damage, and a low
background expression of TP53, which may be sufficient
to sustain the apoptotic pathway.
To examine whether transient suppression of p53 had
a negative effect on the long-term stability of iPSCs, we
performed detailed characterization of iPSC lines estab-
lished w/wo transient p53 suppression. All iPSC lines
were highly similar with respect to expression of plurip-
otency markers and showed a comparable upregulation
of TP53 and downregulation of P21 compared to NHDFs.
Methylation analyses showed a comparable hypomethy-
lation of the pluripotency-associated genes OCT4,
NANOG, SALL4, and RAB25 and hypermethylation of
the fibroblast-specific gene UBE1L, as previously reported
for iPSCs and ESCs (Nishino et al., 2011). Furthermore,
genome-wide transcriptome analyses showed no signifi-
cant up- or downregulated genes and analysis with Plu-
riTest, which is a fast and ethically superior alternative
to teratoma assays in mice (Buta et al., 2013), showed
that all the iPSC lines clustered within the predefined
pluripotency and novelty scores. Finally, in vitroNormal In Vitro Characteristics
emical staining of induced pluripotent stem cells (iPSCs) generated
potency markers OCT3/4, TRA1-81, and Hoechst (B and F), NANOG,
and H).
OU5F1 (OCT4), SOX2, NANOG, DNMT3B, and TP53 and P21. Relative
ermal fibroblasts (NHDFs) as reference. A commercial iPSC line (SBI)
POU5F1 (OCT4), SAL4, RAB25, and UBE1L. Each row represents a
present unmethylated sites and black circles represent methylated
erence iPSC line (SBI) and NHDFs. The PluriTest results are plotted in
s (red cloud) and somatic cells (blue cloud).
L and P), plated EBs on day 28 (M and Q), and immunocytochemical
actin (SMA), and alpha-fetoprotein (AFP) (O and S).
200 mm (N, O, R, and S). See also Figure S3 and Tables S1–S3.
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Figure 4. iPSCs Generated by Transient p53 Suppression Can Differentiate to Functional Neurons In Vitro
(A) Timeline showing the directed neural differentiation of induced pluripotent stem cell (iPSC) lines generated with or without (w/wo) a
short hairpin to p53 (shp53).
(legend continued on next page)
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to generate cells of the three germ layers. To date, some
of the iPSC lines (K1 and K1_shp53) have been cultured
for more than 35 passages, without showing signs of
reduced proliferation.
iPSCs present an ideal system for studies on genomic
stability and confer the ability to determine whether a
given alteration is new, because the parental cells can
also be analyzed (Laurent et al., 2011). The iPSC lines
generated w/wo shp53 displayed normal karyotypes, and
structural CNV analyses showed that they contained be-
tween zero and five CNVs (1.66 CNVs in average), which
were not present in the parental NHDFs. These numbers
are comparable with recent reports using single-nucleotide
variants (SNVs) analyses that reported an average of five
coding mutations, of which around half was preexisting
in the parental fibroblasts (Cheng et al., 2012; Gore
et al., 2011). Moreover, no significant difference between
the overall numbers of CNVs in iPSC lines generated w/
wo transient p53 suppression was found, thus corrobo-
rating recent studies that demonstrated that episomal re-
programming is not inherently mutagenic (Cheng et al.,
2012; Gore et al., 2011).
Lin and colleagues reported that tp53 knockout ESC
showed impaired differentiation and remained in a plurip-
otent state (Lin et al., 2005). In contrast, transient p53
suppression did not affect the neural differentiation po-
tential, and all the iPSC lines successfully formed NPCs
and functional neurons. Recently, transplantation of
NPCs from plasmid-derived iPSCs (Yu et al., 2009) was re-
ported to increase the neurovascular coupling and be-
havioral recovery in a mouse model of ischemic stroke
without any signs of tumor formation 1 year after trans-
plantation (Mohamad et al., 2013). In accordance, trans-
plantation of NPCs from the iPSC lines established by
transient p53 suppression in relevant animal models
would be highly useful for evaluation of safety and effi-
cacy in regenerative stem cell therapy.
The present study demonstrates that transient p53 sup-
pression increases reprogramming efficiency without af-
fecting apoptosis and DNA damage. Furthermore, iPSC
lines generated w/wo transient p53 suppression are iden-
tical with respect to their pluripotent phenotype, their
mutational load, and their differentiation capacity, ren-(B–I) Phase contrast morphology of neuroepithelium (NE) at day 12
neurons at day 35 (D, E, H, and I).
(J–Q) Immunocytochemistry of NPCs at day 21 with SOX2, NESTIN, and
of neurons at day 35 with TUJI and Hoechst (L–P) and vGLUT and Ho
(R–U) Intracellular calcium kinetics in iPSC-derived neurons generate
was recorded for 10 min before application of 300 mM glutamate/10 m
fluorescence was normalized to the first data point of each of the tra
Scale bars, 200 mm (B–D, F–H, and J–Q) and 100 mm (E and I).
Stem Celldering the method suitable for in vitro studies on patient-
specific disease pathology with a potential for clinical
translation.EXPERIMENTAL PROCEDURES
A complete description of experimental procedures can be found
in Supplemental Experimental Procedures.
Reprogramming
Normal human dermal fibroblasts (NHDFs; Lonza) were electropo-
rated with plasmids encoding hOCT4 or hOCT4 with a short
hairpin to TP53 (shp53) in combination with hSOX2, hKLF4,
hL-MYC, and hLIN28 (Addgene plasmids 27076, 27077, 27078
and 27080), abbreviated hOSKUL or hOSKUL+ shp53, respectively
(Okita et al., 2011, 2013) and cultured in mTeSR1 medium (STEM-
CELL Technologies) and Matrigel-coated dishes (BD Biosciences)
from day 7 to day 28.
Flow Cytometry and Apoptotic Measurements
Flow cytometry was performed with monoclonal antibodies
against SSEA4 and TRA1-60 (BD Biosciences), p53, p21, H2A.X
(Cell Signaling Technology), and PUMA (Novus Biologicals) on
a FACSarray Bioanalyzer or a BD Accuri C6 (BD Biosciences). Un-
labeled and isotype-labeled NHDFs were used as controls for
gating.
Characterization of iPSC Lines
Six iPSC lines were established with hOSKUL (K1, K2, and K3) or
hOSKUL + shp53 (K1_shp53, K2_shp53, and K3_shp53) and char-
acterized at passage 10 according to established pluripotency
criteria (Martı´ et al., 2013). Genome-wide transcriptome analysis
was performed using theHT12 v4 BeadChipmicroarray (Illumina).
DNA methylation analyses were performed with the Cells-to-CpG
Bisulfite Conversion Kit (Life Technologies), and PCR-amplified
sequences from ten clones per chromosomal region were exam-
ined. Primers are specified in Table S2.
Chromosome Studies and Copy Number Variation
Analyses
Metaphase chromosomes were investigated with G-banding using
standard procedures. Copy number variation (CNV) analysis was
performed using the high resolution CytoScan HD chromosome
microarray platform (Affymetrix), and data were processed using
Affymetrix Chromosome Analysis Suite (ChAS) and manually
corrected for false-positive hits.(B and F), neural progenitor cells (NPC) at day 21 (C and G), and
Hoechst (J and N) and VIMENTIN, OCT4, and Hoechst (K and O) and
echst (M and Q).
d without (R and S) or with shp53 (T and U). Baseline fluorescence
M glycine, 25 mM K+, 100 mM GABA and 300 mM acetylcholine. The
ces.
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Directed neural differentiation was carried out according to Shi
et al. (2012). Primary antibodies are listed in Table S3.
Statistical Analyses
Statistical analyses comprised a two-tailed Student’s t test with
*p < 0.05 considered significant.
ACCESSION NUMBERS
The GEO (http://www.ncbi.nlm.nih.gov/geo/) accession number
for the microarray data reported in this paper is GSE48665. CNV
raw data are available upon request.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and three tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2014.07.
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